In this video, Sean Riley from New Hampshire shares his health journey with amyloidosis, a rare genetic condition caused by mutations in certain genes that lead to the abnormal production of amyloid proteins.
On September 30, 2024, the Centers for Medicare and Medicaid Services (CMS) issued a Decision Memo titled “Final National Coverage Determination (NCD) for Pre-Exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV) Prevention”
In this video, Bethany from Ohio shares her health journey with schizophrenia and depression, and side effects from going off her medication. She spent a year trying different anti-psychotic medications.
Now Available: Access, Affordability, and Outcomes: The Value of Managed Care Pharmacy Report 2024. On Oct. 10, AMCP unveiled the 2024 edition of Access, Affordability, and Outcomes: The Value of Managed Care Pharmacy report.
On Sept. 20, 2024, the Centers for Medicare & Medicaid Services (CMS) issued a final rule on the Medicare Drug Rebate Program (MDRP). Access the Regulatory NewsBREAK to learn more.
Get quick answers to some of the most common questions on GLP-1 therapies. Get quick answers to some of the most common questions on GLP-1 therapies. Explore how these treatments fit into managed care pharmacy and the nuances of managing this class.
On Sept. 13, 2024, the Internal Revenue Service (IRS), Employee Benefits Security Administration (EBSA), and Centers for Medicare & Medicaid Services (CMS) (collectively, the Departments) released a Final Rule on Requirements Related to the Mental Health Parity and Addiction Equity Act (Final Rule). The Final Rule will be published in the Federal Register on Sept. 23, 2024. Access the Regulatory NewsBREAK to learn more.
On Sept. 13, 2024, the Centers for Medicare & Medicaid Services (CMS) issued a memorandum on Reporting Routing Values for the Medicare Prescription Payment Plan (M3P). Access the Regulatory NewsBREAK to learn more.
On September 9, AMCP submitted comments praising CMS’s proposal to cover Digital Mental Health Treatment devices (DMHTs) under Medicare Part B. AMCP urges CMS to use its authority to cover all FDA-cleared, prescription only digital health products and develop appropriate coding and payment methodologies to promote adoption of these innovative technologies.
SB 966, California's PBM reform bill, could reshape pharmacy benefit manager regulation if signed into law. Governor Newsom’s decision is expected by September 30.
